Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065468 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT00065468 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 626 participants.
The verdict
NCT00065468, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.
Interventions
- DRUG CCI-779
- DRUG Interferon Alfa
- DRUG Interferon Alfa and CCI-779
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065468
The ClinicalTrials.gov registry entry for NCT00065468 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 626 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CCI-779 is the first listed.
NCT00065468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065468 about?
NCT00065468 is a clinical study titled "Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma". The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Inter...
What is the current status of trial NCT00065468?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2003-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00065468?
The interventions under investigation include: CCI-779 (DRUG), Interferon Alfa (DRUG), Interferon Alfa and CCI-779 (DRUG).
Who is sponsoring clinical trial NCT00065468?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.